BRPI0610090A2 - terapia de combinaÇço compreendendo diaril urÉias para tratar doenÇas - Google Patents

terapia de combinaÇço compreendendo diaril urÉias para tratar doenÇas

Info

Publication number
BRPI0610090A2
BRPI0610090A2 BRPI0610090-2A BRPI0610090A BRPI0610090A2 BR PI0610090 A2 BRPI0610090 A2 BR PI0610090A2 BR PI0610090 A BRPI0610090 A BR PI0610090A BR PI0610090 A2 BRPI0610090 A2 BR PI0610090A2
Authority
BR
Brazil
Prior art keywords
ureas
combination therapy
treat diseases
diary
urea compound
Prior art date
Application number
BRPI0610090-2A
Other languages
English (en)
Inventor
Claus Garbe
Birgit Schittek
Friedegund Meier
Urban Scheuring
Ingo Bernard
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of BRPI0610090A2 publication Critical patent/BRPI0610090A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

TERAPIA DE COMBINAÇçO COMPREENDENDO DIARIL URÉIAS PARA TRATAR DOENÇAS. A presente invenção refere-se às composições farmacêuticas e combinações para tratar câncer, compreendendo um composto de diaril uréia e um caminho de sinalização de inibidor de PI3K/AKT. Combinações úteis incluem, por exemplo, BAY-43-9006 como um composto de diaril uréia.
BRPI0610090-2A 2005-05-27 2006-05-13 terapia de combinaÇço compreendendo diaril urÉias para tratar doenÇas BRPI0610090A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05011476 2005-05-27
EP05011478 2005-05-27
EP05011475 2005-05-27
PCT/EP2006/004523 WO2006125539A2 (en) 2005-05-27 2006-05-13 Combination therapy comprising diaryl ureas for treating diseases

Publications (1)

Publication Number Publication Date
BRPI0610090A2 true BRPI0610090A2 (pt) 2008-12-09

Family

ID=37052960

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0610090-2A BRPI0610090A2 (pt) 2005-05-27 2006-05-13 terapia de combinaÇço compreendendo diaril urÉias para tratar doenÇas

Country Status (10)

Country Link
US (1) US20090306020A1 (pt)
EP (1) EP1888065A2 (pt)
JP (1) JP2008545670A (pt)
KR (1) KR20080012902A (pt)
AU (1) AU2006251428A1 (pt)
BR (1) BRPI0610090A2 (pt)
CA (1) CA2609387A1 (pt)
IL (1) IL187085A0 (pt)
MX (1) MX2007014920A (pt)
WO (1) WO2006125539A2 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7838541B2 (en) 2002-02-11 2010-11-23 Bayer Healthcare, Llc Aryl ureas with angiogenesis inhibiting activity
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
WO2004113274A2 (en) 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
RS52625B (sr) 2003-07-23 2013-06-28 Bayer Healthcare Llc Fluoro supstituisana omega-karboksiaril difenil urea za lečenje i prevenciju bolesti i stanja bolesti
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
KR101335932B1 (ko) * 2005-03-07 2013-12-04 바이엘 헬스케어 엘엘씨 암의 치료를 위한 오메가-카르복시아릴 치환된 디페닐우레아를 포함하는 제약 조성물
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
TW200835507A (en) * 2006-12-05 2008-09-01 Vioquest Pharmaceuticals Inc Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
EP2129376B1 (en) 2007-01-19 2013-07-24 Bayer HealthCare LLC Treatment of cancers with acquired resistance to KIT inhibitors
US7947723B2 (en) 2008-02-01 2011-05-24 Spelman College Synthesis and anti-proliferative effect of benzimidazole derivatives
US8586802B2 (en) * 2008-04-09 2013-11-19 Dow Global Technologies Llc Multi-stage process and apparatus for recovering dichlorohydrins
TW201012467A (en) * 2008-09-16 2010-04-01 Taiho Pharmaceutical Co Ltd Antitumor agent containing 4-[[3,5-bis(trimethylsilyl)benzoyl]amino]benzoic acid
MX2011010631A (es) * 2009-04-09 2012-01-20 Oncothyreon Inc Metodos y composiciones de inhibidores de quinasa pi-3 para tratar fibrosis.
IN2012DN02534A (pt) 2009-09-16 2015-08-28 Avila Therapeutics Inc
US20110269244A1 (en) 2009-12-30 2011-11-03 Petter Russell C Ligand-directed covalent modification of protein
ES2385276B1 (es) * 2010-02-25 2013-07-05 Universidad Del País Vasco Compuestos para el tratamiento de alzheimer.
US20130183268A1 (en) 2010-07-19 2013-07-18 Bayer Healthcare Llc Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
WO2015095819A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatment using combinations of erk and raf inhibitors
WO2015095842A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
CN114751899B (zh) * 2022-04-24 2024-03-29 贵州医科大学 一种二芳基脲类mTOR激酶抑制剂及其药物组合物和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378725A (en) * 1993-07-19 1995-01-03 The Arizona Board Of Regents Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof
EP1140840B1 (en) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7838541B2 (en) * 2002-02-11 2010-11-23 Bayer Healthcare, Llc Aryl ureas with angiogenesis inhibiting activity
AU2003226250B2 (en) * 2002-04-08 2007-08-16 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
RS52625B (sr) * 2003-07-23 2013-06-28 Bayer Healthcare Llc Fluoro supstituisana omega-karboksiaril difenil urea za lečenje i prevenciju bolesti i stanja bolesti
MXPA06010667A (es) * 2004-03-19 2007-07-04 Penn State Res Found Metodos combinatorios y composiciones para el tratamiento de melanoma.
ES2368930T3 (es) * 2004-09-06 2011-11-23 Bayer Pharma Aktiengesellschaft Pirazolopirimidinas como inhibidores de proteína cinasa b (akt).

Also Published As

Publication number Publication date
MX2007014920A (es) 2008-04-09
CA2609387A1 (en) 2006-11-30
WO2006125539A3 (en) 2007-03-08
EP1888065A2 (en) 2008-02-20
WO2006125539A2 (en) 2006-11-30
JP2008545670A (ja) 2008-12-18
KR20080012902A (ko) 2008-02-12
AU2006251428A1 (en) 2006-11-30
IL187085A0 (en) 2008-08-07
US20090306020A1 (en) 2009-12-10

Similar Documents

Publication Publication Date Title
BRPI0610090A2 (pt) terapia de combinaÇço compreendendo diaril urÉias para tratar doenÇas
BRPI0511139B8 (pt) compostos que inibem quinase aurora e composição farmacêutica contendo os mesmos
ECSP10010042A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
PA8637201A1 (es) Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
TW200744586A (en) Therapeutic compounds
AR063628A1 (es) Compuestos de piridinona utiles para el tratamiento de cancer
ECSP105178A (es) Compuestos de aril urea en combinación con otros agentes citostáticos o citotóxicos para el tratamiento de cáncer en humanos
BR112012009376B8 (pt) composição farmacêutica sólida compreendendo um inibidor de sglt-2 e sua forma de dosagem farmacêutica
MX2009007944A (es) Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
MX2011013176A (es) Motivos de modificación química para inhibidores y miméticos del miarn.
HN2006009702A (es) Composicion farmaceutica para el tratamiento del cancer
ECSP088749A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
MX2011008899A (es) Nuevas orto-aminoamidas para el tratamiento del cancer.
MX2009002054A (es) Metodos para inhibir angiogenesis y tratamiento contra enfermedades asociadas con angiogenesis.
BRPI0820668A2 (pt) Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina
AR056801A1 (es) Terapia combinada anti- proliferativa con determinados agentes quimioterapeuticos basados en platino e inhibidores de egfr o analogos de pirimidina
DE602006016449D1 (pt)
CO2022016754A2 (es) Moléculas de fijación para el tratamiento de cáncer
BRPI0507626A (pt) compostos e composiçoes como moduladores de lxr
UY29161A1 (es) Nuevos heterociclos
MX2008002166A (es) Compuestos y composiciones como mimeticos de trombopoietina (tpo).
MX2010000223A (es) Compuestos de triazina novedosos para el tratamiento de cancer.
WO2010031708A3 (en) Ortho-aminoanilides for the treatment of cancer
DE602006012313D1 (de) Kombination aus pyrimidylaminobenzamid-verbindungen und imatinib zur behandlung oder verhinderung proliferativer erkrankungen

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]